| Literature DB >> 14579267 |
Florian Heil1, Parviz Ahmad-Nejad, Hiroaki Hemmi, Hubertus Hochrein, Franziska Ampenberger, Tanja Gellert, Harald Dietrich, Grayson Lipford, Kiyoshi Takeda, Shizuo Akira, Hermann Wagner, Stefan Bauer.
Abstract
Loxoribine (7-allyl-7,8-dihydro-8-oxo-guanosine) acts as synthetic adjuvant in anti-tumor responses. Here we first demonstrate that loxoribine activates cells of the innate immune system selectively via the Toll-like receptor (TLR) 7/MyD88-dependent signaling pathway. TLR7- and MyD88-deficient immune cells fail to proliferate or produce cytokines in response to loxoribine, and genetic complementation of TLR7-deficient cells with murine or human TLR7 confers responsiveness. Subsequently we show that cellular activation by loxoribine and resiquimod (R-848), a stimulus for TLR7 and TLR8, depends on acidification and maturation of endosomes and targets MyD88 to vesicular structures with lysosomal characteristics. This mode of TLR7 and TLR8 action resembles CpG-DNA-driven TLR9 activation. We thus conclude that TLR7, 8 and 9 form a functional subgroup within the TLR family that recognizes pathogen-associated molecular patterns in endosomal/lysosomal compartments.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14579267 DOI: 10.1002/eji.200324238
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532